Genagon Theraputics AB

Genagon has developed a platform to identify novel pathways in immune cells and discovered a new mechanism which cancers use to inhibit the innate immune system: Macrophages, Dendritic cells, and NK-cells. These cells are essential to recruit, train, and activate cancer specific T-cells to attack and destroy their target. By blocking these inhibitory pathways Genagon will increase response rates in immuno-oncology.